For immunochemical detection of YTHDC2
Related Products
Measurement and Detection Tool(s)
26344YTHDC2 (human, recombinant)
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

YTHDC2 Polyclonal Antibody

Item No. 28224

Technical Information
Synonyms
  • hYTHDC2
  • 3'-5' RNA Helicase YTHDC2
  • YTH Domain-containing Protein 2
Immunogen
Full-length recombinant human YTHDC2 protein
MW
160 kDa
500 µg of protein A-purified polyclonal antibody
Storage Buffer
PBS, pH 7.2, with 50% glycerol and 0.02% sodium azide
Host
Rabbit
Applications
IF, IHC and WB
Species Reactivity
(+) Human
UniProt Accession №
Q9H6S0
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    YTH domain containing 2 (YTHDC2) is an ATP-dependent 3’-5’ RNA helicase and a member of the DExD/H-box family of helicases.1 YTHDC2 contains ATP binding, ATP hydrolysis, and RNA binding motifs.1 The aYTH domain binds to N6-methyladenosine-modified germline messenger RNA to regulate meiotic gene expression in mammalian germ cells, mediating the mitotic-to-meiotic transition in mouse germ cells.2,3 Ythdc2-/- male and female mice show disrupted meiotic prophase progression.3 Male Ythdc2-/- mice have degraded germ cells and lack mature spermatozoa, while female Ythdc2-/- mice lack developing ovarian follicles and have few germ cells. YTHDC2 also facilitates hepatitis C virus (HCV) genome replication by binding to the HCV replication cofactor cyclophilin B and the HCV RNA polymerase non-structural protein 5B (NS5B).4 YTHDC2 downregulation inhibits proliferation in Huh7 hepatocellular carcinoma cells and reduces metastasis a Y2KD-116 mouse xenograft model using HCT116 cells in which YTHDC2 is downregulated.4,5 The expression of YTHDC2 in isolated human tumor tissue is positively correlated with tumor stage and lymph node metastasis.5 Cayman’s YTHDC2 Polyclonal Antibody can be used for immunofluorescence, immunohistochemistry, and Western blot applications. The antibody recognizes YTHDC2 at 160 kDa from human samples.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Tanabe, A., Konno, J., Tanikawa, K., et alTranscriptional machinery of TNF-α-inducible YTH domain containing 2 (YTHDC2) gene. Gene 535(1), 24-32 (2014).

    2. Wojtas, M.N., Pandey, R.R., Mendel, M., et alRegulation of m6A transcripts by the 3'→5' RNA helicase YTHDC2 is essential for a successful meiotic program in the mammalian germline. Mol. Cell 68(2), 374-387 (2017).

    3. Bailey, A.S., Batista, P.J., Gold, R.S., et alThe conserved RNA helicase YTHDC2 regulates the transition from proliferation to differentiation in the germline. Elife pii:e26116, (2017).

    4. Morohashi, K., Sahara, H., Watashi, K., et alCyclosporin A associated helicase-like protein facilitates the association of hepatitis C virus RNA polymerase with its cellular cyclophilin B. PLoS One 6(4):e18285, (2011).

    5. Tanabe, A., Tanikawa, K., Tsunetomi, M., et alRNA helicase YTHDC2 promotes cancer metastasis via the enhancement of the efficiency by which HIF-1α mRNA is translated. Cancer Lett. 376(1), 34-42 (2016).